TD Cowen lowered the firm’s price target on Idex Corp. to $215 from $235 and keeps an Outperform rating on the shares. The firm believesthe company will be a go-to for industrial investors to play a medical bottom at the appropriate time but acknowledge that an overall organic revenue and EPS decline next year is likely now given YTD orders.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on IEX: